To assess the effectiveness of different types of taxanes, including nab-paclitaxel, paclitaxel and docetaxel, and further compare the effectiveness of taxane-based chemotherapy, taxane-based chemotherapy plus angiogenesis inhibitors or taxane-based chemotherapy plus immune checkpoint inhibitors in HER2-altered non-small-cell lung cancer in the second- or third-line setting....Taxane-based chemotherapy plus immune checkpoint inhibitors achieved longer progression-free survival than taxane-based chemotherapy.

Stage IV NSCLC patients with HER2 alteration were retrospectively analyzed from 6 cancer centers in China between May 2017 and February 2023....Compared with chemotherapy, combination therapy significantly improved mPFS (8.47 months VS 4.97 months, p<0.0001). Further analysis based on different combination mode showed that, each of the combination therapeutics, including BC (mPFS 7.27 m, HR=0.31, 95% CI: 0.14-0.68, p<0.001), IC (mPFS 8.47m, HR=0.20, 95% CI:0.08-0.48, p=0.004) and IBC (mPFS 16.3m, HR=0.08, 95% CI: 0.02-0.25, p<0.001), gave beneficial PFS compared with chemotherapy.

For ERBB2-mutant patients, the mPFS was 5.9 months, and Chemo+Immuno and Chemo+Antiangio both achieved longer mPFS than TKI (12.9 vs 2.9 months, HR: 0.15, 95%CI: 0.03-0.68, P=0.005; 7.1 vs 2.9 months, HR: 0.50, 95%CI: 0.29-0.88, P=0.009, respectively).

We compared the progression-free survival (PFS) of 324 advanced NSCLC patients who received ICI monotherapy (as over second-line therapy) by different AGAs....A total of 324 patients were included with the following AGAs: EGFR mutation (n = 149, 46.0%), ALK rearrangement, (n = 12, 3.7%), KRAS mutation (n = 72, 22.2%), HER2 mutation or amplification (n = 34, 10.5%), and MET ex14 skipping or amplification (n = 32, 9.9%), ROS1 rearrangement (n = 9, 2.8%), BRAF V600E (n = 9, 2.8%), and RET rearrangement (n = 7, 2.2%).....The 6-month PFS rate was 25.8% (19.5–34.3) in the group with KRAS/BRAF V600E/MET/HER2 and 12.8% (8.6–19.1) in the group with EGFR/ALK/ROS1/RET (P < 0.01)...the KRAS/BRAF V600E/MET/HER2 group had a favorable PFS compared with the EGFR/ALK/ROS1/RET group.

HER2-altered NSCLC patients who received taxanes-based treatment as the second or third-line setting between November 2015 and September 2021 were screened….A total of 52 patients were finally included. C+I achieved longer PFS than C (median, 5.70 vs.4.27 months, hazard ratio 0.39, 95% CI: 0.16-0.92, p=0.003). A clinically meaningful improvement in PFS was observed among patients in the nab-paclitaxel group compared with those in the docetaxel group (median, 6.40 vs. 4.03 months, hazard ratio 0.34, 95%CI: 0.16-0.71, p=0.003)....In the taxanes, nab-paclitaxel might improve survival outcomes than docetaxel for HER2-altered patients. Chemotherapy plus immune checkpoint inhibitors might yield more survival benefits than chemotherapy alone in the second or third-line setting in HER2-altered NSCLC.

The ORR and PFS were 16.7% (n = 12) and 28.6% (n = 7), 7.8 months and 9.0 months for HER2 and EGFR Exon20 insertion patients, respectively. Three ROS1 patients were enrolled with a PFS of 16.0, 34.2, and 45.0 months individually, and one ALK patient with PFS of 4.4 months was identified....ICI-based combination therapy could be considered for patients with ROS1 rearrangement, HER2 mutation and EGFR Exon20 insertion NSCLC.

We conducted a multicenter retrospective study of patients with HER2-mutant lung adenocarcinoma who received ICIs therapy...Among the 9 patients receiving ICIs-based therapy as first-line treatment, 5 patients had partial response (PR) and 4 patients had stable disease (SD), with a median PFS of 9.1 months....Our retrospective study provides clinical evidence that front line of ICIs-based therapy is also worth considering for the treatment to improve survival outcomes of patients with HER2-mutant lung adenocarcinoma.

...retrospectively assessed outcomes of HER2mu NSCLC patients treated with ICI...ICI in combination with chemotherapy the ORR, median PFS, and OS rate at 1 year were 52%, 6 months, and 88%, respectively. In second or later lines ICI monotherapy was associated with an ORR of 16%, a median PFS of 4 months, and a median OS of 10 months....Immune checkpoint inhibitors are effective as monotherapy and in combination with platinum doublet chemotherapy.

This retrospective single-center study analyzed patients with EGFR- and HER2-mutated advanced NSCLC who received at least 1 cycle of ICI between 2013 and 2019….HER2 and EGFR exon 20 mutations derive greater benefit from ICIs with comparable PFS to wild-type...